Skip to main content

Advertisement

SpringerLink
Log in

Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development

  • Systemic Therapy (J Cortes, Section Editor)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Topoisomerases are enzymes involved in the replication of DNA and they are the target of the topoisomerase inhibitors 1 and 2. This class of anticancer agents forms the backbone of chemotherapeutic regimens in several solid tumors including breast cancer. This review focuses on their role in the treatment of metastatic breast cancer. While anthracyclines (topoisomerase 2 inhibitors) are commonly used in metastatic breast cancer, other agents such as the topoisomerase 1 inhibitors and etoposide have reached some level of clinical development. New formulations of doxorubicin are frequently used in the clinic and a new formulation of irinotecan, and etirinotecan pegol, has recently reached phase 3 development. An overview of their mechanism of action, toxicity, and clinical use (single agent or combination settings) is provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Recently published papers of particular interest have been highlighted as:• Of importance •• Of major importance

  1. Aftimos P, Awada A. Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: What next? Adv Ther. 2011;28:973–85.

    Article  PubMed  CAS  Google Scholar 

  2. Hande K. Topoisomerase II, inhibitors. Update on Cancer Therapeutics. 2008;3:13–26.

    Article  Google Scholar 

  3. Rothenberg ML. Topoisomerase I, inhibitors: review and update. Ann Oncol. 1997;8:837–55.

    Article  PubMed  CAS  Google Scholar 

  4. • Moukharskaya J, Verschraegen C. Topoisomerase 1 inhibitors and cancer therapy. Hematol Oncol Clin North Am. 2012;26:507–25. This article provides a comprehensive synthesis of topoisomearases I inhibitors.

  5. Haglof K, Popa E, Hochster S. Recent developments in the clinical activity of topoisomerase I inhibitors. Update on Cancer Therapeutics I. 2006;117–45.

  6. Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol. 2008;75:1262–71.

    Article  PubMed  CAS  Google Scholar 

  7. Wildiers H, Higley MS, de Bruijn EA, Van oosterom AT. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet. 2003;42:1213–42.

    Article  PubMed  CAS  Google Scholar 

  8. Taguchi T, Yoshida Y, Izuo M, et al. An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer. Gan To Kagaku Ryoho. 1994;21:83–90.

    PubMed  CAS  Google Scholar 

  9. Taguchi T, Tominaga T, Ogawa M, et al. A late phase II study of CPT-11 in advanced breast cancer. Gan To Kagaku Ryoho. 1994;21:1017–24.

    PubMed  CAS  Google Scholar 

  10. Shigeoka Y, Kuniaki I, Tadahiko I, et al. Clinical effect of Irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin and docetaxel containing regimens. Jpn J Clin Oncol. 2001;31:370–4.

    Article  PubMed  CAS  Google Scholar 

  11. Perez E, Hillman D, Maillard J, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane or both. J Clin Oncol. 2004;22:2849–55.

    Article  PubMed  CAS  Google Scholar 

  12. Hayashi H, Junji T, Taro S, et al. Phase II study of bi-weekly irinotecan for patients with previously treated HER 2 negative metastatic breast cancer: KMBOG0610B. Breast Cancer. 2011. doi:10.1007/s12282-011-0316-z.

  13. Stathopoulos GP, Tsavdaridis D, Malamos NA, et al. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer Chemother Pharmacol. 2005;56:487–91.

    Article  PubMed  CAS  Google Scholar 

  14. Frasci G, D’Aiuto G, Thomas R, et al. Biweekly docetaxel-Irinotecan treatment with Filgastrim support is higly active inantracycline-Paclitaxel refractory breast cancer patient. Oncology. 2005;68:391–7.

    Article  PubMed  CAS  Google Scholar 

  15. Tan W, Hillman W, Salim M, et al. NO332 phase II trial of weekly Irinotecan hydrochloride, and Docetaxel in refractory metastatic breast cancer: a north central cancer treatment group (NCCTG) trial. Ann Oncol. 2010;21:493–7.

    Article  PubMed  CAS  Google Scholar 

  16. Moulder S, Munster P, Minton S, et al. Results of a planned efficacy and safety analysis for a NCCN phase II study of Gemcitabine and Irinotecan in metastatic breast cancer. J Clin Oncol. 2005;23:Abstract 679: http://www.asco.org/.

  17. Moulder S, Valkov N, Minton S. A single arm Phase II trial of Gemcitabine and irinotecan in metastatic breast cancer: can localization of topoisomerase I predict response of TOPO I inhibitors. J Clin Oncol. 2006;Abstract 661: http://www.asco.org/.

  18. Mrozek E, Kolesar J, Allen J, et al. Phase II study of sequentially administered mitomycine and Irinotecan in women with metastatic breast cancer. Ann Oncol. 2008;19:1417–22.

    Article  PubMed  CAS  Google Scholar 

  19. Lee KS, Park IH, Nam BH. Phase II study of irinotecan plus capecetabine in antracyclines and taxane pretreated patients with metastatic breast cancer. Invest New Drugs. 2012. doi:10.1007/s10637-012-9824-8.

  20. Chang AY, Garrow G, Boros L, Asbury R, et al. Clinical and laboratory studies of Topotecan in breast cancer. ASCO. 1995;Abstract 118: http://www.asco.org/.

  21. Goldschimdt E, Bonneterre J, Fumoleau P, et al. A phase II study of Topotecan on a daily x 5schedule as second line therapy in patients with advanced breast cancer. ASCO 1997;Abstract 598; http://www.asco.org/.

  22. Spaeth D, Bonneterre J, Marty M, Khayat D, Facchini T, Conroy T. Phase II study of two trial regimens of Topotecan second line agent therapy in advanced breast cancer. ASCO. 1997;Abstract 675: http://www.asco.org/.

  23. Levine EG, Cirrincione CT, Statrowski TP, Canellos, et al. Phase II trial of Topotecan in advanced breast cancer: a cancer and leukemia group B study. Am J Clin Oncol. 1999;22:218–22.

    Article  PubMed  CAS  Google Scholar 

  24. Eymard JC, Fumoleau P, Bourgeois H. et al. A phase II study of oral Topotecan as single agent, third line therapy, in women with metastatic breast cancer. ASCO. 1999;Abstract 430: http://www.asco.org/.

  25. Ishmael D, Wei R, Chen R, Nordquist RE. Phase I trial of concurrent Topotecan and Docetaxel administered every 2 weeks times 3, courses repeated every 8 weeks in patients with breast and lung cancer. Proc Am Soc Clin Oncol. 21:2002;Abstract 2158: http://www.asco.org/.

  26. Oberhoff C, Kieback DG, Wurstein R, Deert H, et al. Topotecan chemotherapy in patient with breast cancer and brain metastases: a pilot study. Onkologie. 2001;24(3).

  27. GlaxoSmithKline. Brain metastases in ErbB2-Positive breast cancer. ClinicalTrials.gov Identifier: NCT00437073.

  28. Kraut EH, Balcerzak SP, Young D, O’Rourke MA, et al. A phase II study of 9-aminocamptothecin in patients with refractory breast cancer. Cancer Invest. 2000;1:28–31.

    Article  Google Scholar 

  29. Takimoto H, Rebecca T. The clinical development of 9-aminocamptothecin. The camptothecin: unfolding their anticancer potential. Ann NY Acad Sci. 2000;922:224–36.

    Google Scholar 

  30. Miller KD, Soule SE, Haney LG, et al. A phase II study of 9- nitrocamptothecin in patients with previously treated metastatic breast cancer. Invest New Drugs. 2004;22:69–73.

    Article  PubMed  CAS  Google Scholar 

  31. Chedid S, Rivera E, Frye DK, et al. Minimal clinical benefit of single agent orathecin (rubitecan) in heavily pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2006;57:540–4.

    Article  PubMed  CAS  Google Scholar 

  32. Esteva JF, Rivera E, Massimo C. A phase II study of intravenous exatecan mesylate (DX-8951 f) administrated daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer. 2003;98:900–7.

    Article  PubMed  CAS  Google Scholar 

  33. Giannie L, Hess D, Baselga J. A phase I study of the oral camptothecin gimatecan with a design of concerted dose escalation in 3 schedules of different dosing-duration. Proc Am Soc Clin Oncol. 2003; 22:Abstract 554: http://www.asco.org/.

  34. Zhu AX, Ready N, Clarck JW, et al. Phase I pharmokinetic study of gimatecan given orally once a week for3 weeks in patients with advanced solid tumors. Clinical Cancer Research. 2009;15:374.

    Article  PubMed  CAS  Google Scholar 

  35. Mariani P, Moliterni A, Da Prada G, et al. A phase II trial of the novel oral camptothecin gimatecan in women with anthracycline and taxane pretreated advanced breast cancer. Journal of Clin Oncol. 2006; ASCO:annual meeting proceedings, part I, vol 24, No 18S:Abstract 662: http://www.asco.org/.

  36. Chatterjee A, Raghunaadharao D, Rao M, et al. DRF-1042, a novel orally active camptothecin analog: safety, pharmacokinetic and pharmacodynamics evaluation in a phase I dose escalation study. Proc Am Soc Clin Oncol. 2002;21:Abstract 384: http://www.asco.org/.

  37. Soepenberg O, Dumez H, Verweijde V, et al. Phase I study pharmacokinetic, food effect, and pharmacogenetic study of oral Irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res. 2005;11:1504–11.

    Article  PubMed  CAS  Google Scholar 

  38. Vukelja S, O’Shaughnessy J, Campos S, et al. Activity of oral Irinotecan in metastatic breast cancer after prior anthracyclines, taxane, and capecetabine: Phase II study results. J Clin Oncol. 2005; 23:Abstract 562: http://www.asco.org/.

  39. Von hoff Dd, Jameson GS, Borad MJ, et al. F Phase 1 trial of NKTR-102 (Peg-Irinotecan) reveals early evidence of broad anti-tumor activity in three different schedules. Presented at the 20th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” Meeting, Oct 21–24, 2008;Geneva, Switzerland. Poster no. 595.

  40. •• Awada A, Chan S, Jerusalem R, et al. Antitumor activity in a randomized Phase II study comparing 2 schedules of NKTR -102 in patients with pretreated metastatic breast cancer. J Clin Oncol. 2011; 29(Suppl); Abstract 1034). First report of a phase II trial with a novel and promising agent: etirinotecan pegol. A phase III trial is ongoing.

  41. Nektar Therapeutics. The BEACON Study (Breast Cancer Outcomes with NKTR-102). ClinicalTrials.gov Identifier: NCT01492101.

  42. Hande K. Topoisomerase II inhibitors. Update on cancer therapeutics I. 2006;1:3–15.

  43. Verrill M. Anthracyclines in breast cancer: therapy and issues of toxicity. The Breast. 2001;(Suppl 2):8–15.

  44. Burnell M, Levine MN, Chapman JA, et al. Cyclophosphamide, epirubicin, and Fluorouracil vs dose-dense epirubicin and cyclophosphamide followed by paclitaxel vs doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol. 2010;28:77–82.

    Article  PubMed  CAS  Google Scholar 

  45. Leonard RCF, Williams S, Tulpule A, et al. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomial doxorubicin (Myocet). The Breast. 2009;18:218–24.

    Article  PubMed  CAS  Google Scholar 

  46. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of characteristics, therapeutic activity, and toxicity. Cancer Treat Rev. 1993;19:197–228.

    Article  PubMed  CAS  Google Scholar 

  47. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med. 1979;91:710–7.

    Google Scholar 

  48. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133–9.

    PubMed  CAS  Google Scholar 

  49. Riviera. E. Current status on liposomal anthracyclines therapy in metastatic breast cancer. Clin Breast Cancer. 2003;4(Suppl):76–83.

    Google Scholar 

  50. Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20:1771.

    Article  PubMed  CAS  Google Scholar 

  51. O’Shaughnessy JA, Clark RS, Blum JS, et al. Phase II of pemetrexed in patients pretreated with an anthracycline, a taxane and capecetabine for advanced breast cancer. Clin Breast Cancer. 2005;6:143–149.

    Article  PubMed  Google Scholar 

  52. Esteva FJ, Valero V, Pusztai L, et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001;6:133–46.

    Article  PubMed  CAS  Google Scholar 

  53. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol. 2003;21:588–92.

    Article  PubMed  Google Scholar 

  54. Joensuu H, Holli K, Heikkinen M, et al. Combination chemotherapy vs single agent therapy as first line and second line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol. 1998;16:3720.

    PubMed  CAS  Google Scholar 

  55. The French Epirubin Study Group. A prospective randomized trial comparing epirubicin monotherapy to two fluorouracil, cyclophosphamide and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol. 1991;9:305.

    Google Scholar 

  56. Khasraw M, Bell R, Dang C. Epirubicin: is it like doxorubicin in breast cancer? A clinical review. The Breast. 2012;21:142–9.

    Article  PubMed  Google Scholar 

  57. Findlay BP, Walker-Dilks C, Pritchard K, and members of the breast cancer disease site group and the systemic treatment disease site group: Epirubicin, as a single agent or in combination, for metastatic breast cancer practice guideline Report # 1–6. Practice Guideline Report 1–6 was reviewed in 2010 and archived by the cancer disease site group on June 11 2011.

  58. Biganzoli L. State of the art therapy for Her2-negative metastatic breast cancer. Eur J Cancer. 2008;(Suppl 6):10–15.

  59. Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26:1980–6.

    Article  PubMed  CAS  Google Scholar 

  60. Blohmer JU, Schmid P, Hilfrich J, Friese K, Kleine-Tebbe A, et al. Epirubicin and cyclophosphamide vs epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III trial. Ann Oncol. 2010;21:1430–5.

    Article  PubMed  Google Scholar 

  61. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent, or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60.

    Article  PubMed  CAS  Google Scholar 

  62. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

    Article  PubMed  CAS  Google Scholar 

  63. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.

    Article  PubMed  CAS  Google Scholar 

  64. Slamon J, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

    Article  PubMed  CAS  Google Scholar 

  65. Untch M, Muscholl M, Tjulandin S, et al. First line trastuzumab plus epirubicin and cyclphosphamide in patients with human epidermal growth factor receptor 2 positive MBC: cardiac safety and efficacy data from the Herceptin, cyclophosphamide and epirubicin (HERCULES) trial. J Clin Oncol. 2010;28:1473–80.

    Article  PubMed  CAS  Google Scholar 

  66. Cornbleet M, Stuart-Harris R, Smith I, et al. Mitoxantrone for the treatment of advanced breast cancer: single agent therapy in previously untreated patients. Eur J Cancer Clin Oncol. 1984;20:1141–6.

    Article  PubMed  CAS  Google Scholar 

  67. Neidhart JA, Gochnour D, Roach R, Hoth D, Young D. A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol. 1986;4:672.

    PubMed  CAS  Google Scholar 

  68. Henderson IC, Allegra JC, Woodcock T, et al. Randomized clinical trial comparing mitoxantrone with doxorubicine in previously treated patients with metastatic breast cancer. J Clin Oncol. 1989;7:560.

    PubMed  CAS  Google Scholar 

  69. Cook AM, Chambers EJ, Rees G. Comparison of mitoxantrone and epirubicin in advanced breast cancer. Clin Oncol. 1996;8:363–6.

    Article  CAS  Google Scholar 

  70. Delozier TR, Vernhes JC. Comparative study of Adriamycin, epirubicin and mitixantrone in cancer of the breast. Review of the literature. Bulletin du cancer. 1991;78:1013–5.

    PubMed  CAS  Google Scholar 

  71. Koeller J, Elbe M. Mitoxantrone, a novel anthracycline derivative. College of Pharmacology, University of Texas, Austin. Clin Pharm. 1998;7:574–81.

    Google Scholar 

  72. Schmid P, Flath B, Akrivakis K, et al. Gemcitabine and mitoxantrone in metastatic breast cancer. A phase I study. Investigational New Drugs. 2003;23:349–56.

    Article  Google Scholar 

  73. Bennett JM, Muss HB, Doroshow JH, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluoracil with doxorubicin, cyclophosphamide, and fluoracil in the therapy of metastatic breast cancer. J Clin Oncol. 1988;6:1611.

    PubMed  CAS  Google Scholar 

  74. Alonso MC, Tabernero JM, Ojeda BN, et al. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) vs cyclophosphamide, Adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Breast Cancer Res Treat. 1995;34:15–24.

    Article  PubMed  CAS  Google Scholar 

  75. Estaban E, Lacave AJ, Fernandez JL, et al. Phase III trial of cyclophosphamide, epirubicin, fluoracil(CEF) vs cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic disease. Breast Cancer Res Treat. 1999;58:141–50.

    Article  PubMed  CAS  Google Scholar 

  76. Lemmens J, Berteloot P, Thomas J, Wildiers H, Paridaens R. Mitoxantrone, 5-Fluoracil and Leucovorin in metastatic breast cancer. Eur J Cancer. 1995;31A:2114–5.

    Article  PubMed  CAS  Google Scholar 

  77. Hainsworth JD, Jolivet J, Bich R, Hopkins LG, Greco FA. Mitoxantrone, 5-fluorouracil and high dose leucovorin (NFL) vs intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first line chemotherapy for patients with metastatic breast cancer: a randomized phase II study. Cancer. 1997;15(79):740–8.

    Article  Google Scholar 

  78. Onyenadum A, Gogas H, Kosmidis P, et al. Mitoxantrone plus Gemcitabine in pretreated patients with metastatic breast cancer. J Chemother. 2006;18:192–8.

    PubMed  CAS  Google Scholar 

  79. Onyenadum A, Gogas H, Markopoulos C, Bafaloukos D, Aravantinos G, et al. Mitoxantrone plus vinoreline in pretreated patients with metastatic breast cancer. J Chemother. 2007;19:582–9.

    PubMed  CAS  Google Scholar 

  80. Namer M, Soler-Michel P, Turpin F, Chinet-Charrot P, De Gislain C, Pouillat P, et al. Results of a phase III study prospective, randomized trial, comparing mitoxantrone and vinorelbine in combination with standard FAC/FEC in front-line therapy of metastatic breast-cancer. Eur J Cancer. 2001;37:1132–40.

    Article  PubMed  CAS  Google Scholar 

  81. Hausmaninger H, Lehnert M, Steger G, Sevelda P, Tschurtschenthaler G, et al. Randomized phase II study of epirubicin-vindesine vs mitoxantrone-vindesine in metastatic breast cancer. Eur J Cancer. 1995;31A:2169–73.

    Article  PubMed  CAS  Google Scholar 

  82. Hainsworth JD, Jones SE, Mennel RG, Blum JL, Greco FL. Paclitaxel with mitoxantrone, fluorouracil, and high dose of leucovorin in the treatment of metastatic breast cancer: a phase II trial. J Clin Oncol. 1996;5:1611–6.

    Google Scholar 

  83. Riviera E. Liposomial anthracyclines in metastatic breast cancer: clinical update. The Oncologist. 2003;8 Suppl 2:3–9.

    Article  Google Scholar 

  84. Verma S. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev. 2008;34:391–406.

    Article  PubMed  CAS  Google Scholar 

  85. Gabizon A, Shmeeda H, Grenader T. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur J Pharm Sci. 2012;45:388–98.

    Article  PubMed  CAS  Google Scholar 

  86. Trudeau ME, Clemons MJ, Provencher L, et al. Phase II multicenter trial of anthracyclines rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol. 2009;27:5906–10.

    Article  PubMed  CAS  Google Scholar 

  87. De la Fouchardiere C, Largillier R, Goubely Y, et al. Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE. Ann Oncol. 2009;20:1959–63.

    Article  PubMed  Google Scholar 

  88. Adamo V, Lorusso V, Rossello R, et al. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. Br J Cancer. 2008;98:1916–21.

    Article  PubMed  CAS  Google Scholar 

  89. Christodoulou C, Kostopoulos I, Kalfonos H, et al. Trastuzumab combined with pegylated doxorubicin in patients with metastatic breast cancer. Oncology. 2009;76:275–8.

    Article  PubMed  CAS  Google Scholar 

  90. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444–54.

    PubMed  CAS  Google Scholar 

  91. Curtit E, Nouyrigat D, et al. Myotax: a phase II trial of Docetaxel plus non - pegylated liposomal doxorubicin as first line therapy of metastatic breast cancer previously treated with adjuvant anthracycline. Euro J Cancer. 2011;47:2396–402.

    Article  CAS  Google Scholar 

  92. Del Braco S, Colomer R, Calvo L, et al. Non-pegylated liposomal doxorubicin with gemcitabine as first line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial. Breast Cancer Res Treat. 2009;116:351–358.

    Article  Google Scholar 

  93. Poletti P, Bettini AC, Caremoli E, Labianca R, Tondini C. Liposomal encapsulated doxorubicin (Myocet;D-99) and vinorelbine in previously treated metastatic breast cancer patients: a feasibility study. Tumori. 2008;94:686–90.

    PubMed  CAS  Google Scholar 

  94. Theodoulou M, Batist G, Campos S. Phase I study of non pegylated liposomal doxorubicin in patients with Her2 positive breast cancer. Clin Breast Cancer. 2009;9:101–7.

    Article  PubMed  CAS  Google Scholar 

  95. Venturini M, Bighin C, Puglisi F, Olmeo N, et al. A multicenter Phase II study of non –pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first line therapy in metastatic breast cancer. The Breast. 2010;19:333–8.

    Article  PubMed  CAS  Google Scholar 

  96. Amadorini D, Milandri C, Comella G. A phase I/II trial of non pegylated liposomal doxorubicin, docetaxel, and trastuzumab as first line treatment in HER-2-positive locally advanced or metastatic breast cancer. Euro J Cancer. 2011;47:2091–8.

    Article  Google Scholar 

  97. Yuan P, Xu J-Y, Ma F, Fan Y, Li Q, et al. Oral etoposide is effective for metastatic breast cancer with heavy prior therapy. Chin Med J. 2012;125:775–9.

    PubMed  CAS  Google Scholar 

  98. Fried G, Stein ME, Kuten A, et al. Vinorelbine/VP-16 (etoposide) in metastatic breast cancer: a phase II study. J Buon. 2005;10:201–4.

    PubMed  CAS  Google Scholar 

  99. Icli F, Akbulut H, Uner A, Yalcin B, Baltali E, et al. Cisplatin plus oral etoposide combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomized phase III study of Turkish Oncology Group. Br J Cancer. 2005;92:639–44.

    Article  PubMed  CAS  Google Scholar 

  100. Lu YS, Chen WW, Lin CH, et al. Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: results of the first stage of a multicenter phase II study. J Clin Oncol. 2012;30:Abstract 1079: http://www.asco.org/.

  101. to-BBB technologies B.V. An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. ClinicalTrials.gov Identifier: NCT01386580.

  102. • Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011;29:1578–86. Very provocative paper looking into an immune and genomic signature for anthracyclines sensitivity.

    Article  PubMed  CAS  Google Scholar 

  103. Di Leo A, Desmedt C, Bartlett JM, et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 2011;12:1134–42.

    Article  PubMed  Google Scholar 

Download references

Disclosure

M.-C. Vanderbeeken: none; P.G. Aftimos: none; A. Awada: consultant to Nektar, payment for lectures including service on speakers bureaus from Bayer and Novartis, and payment for development of educational presentations from GlaxoSmithKline.

Author information

Authors and Affiliations

  1. Medical Oncology Clinic, Rue Héger-Bordet 1, 1000, Brussels, Belgium

    Marie-Catherine Vanderbeeken, Philippe G. Aftimos & Ahmad Awada

Authors
  1. Marie-Catherine Vanderbeeken
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philippe G. Aftimos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmad Awada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmad Awada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vanderbeeken, MC., Aftimos, P.G. & Awada, A. Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development. Curr Breast Cancer Rep 5, 31–41 (2013). https://doi.org/10.1007/s12609-012-0098-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-012-0098-0

Keywords

Search

Navigation